Elranatamab displayed a manageable safety profile in patients with relapsed/refractory multiple myeloma (MM) in the phase 2 MagnetisMM-3 trial. Furthermore, the investigational agent demonstrated promising efficacy data, supporting the continued investigation of elranatamab.
Elranatamab is a humanized, bi-specific antibody targeting BCMA-expressing MM cells and CD3-expressing T cells.1 The MagnetisMM-3 study tested this agent in 187 patients with relapsed/refractory MM across two cohorts.2 Dr. Nizar Bahlis (University of Calgary, Canada) presented the results of cohort A, including a patient population that had no prior exposure to BCMA-directed therapy (N=123), at the 2022 annual meeting of the American Society of Hematology. Notably, 96.7% of participants were triple-class refractory at baseline. After two step-up doses of 12 mg and 32 mg, respectively, participants received 76 mg elranatamab, once weekly, subcutaneously administered. The primary endpoint was the objective response rate (ORR) per blinded independent central review.
The confirmed ORR was 61.0%. In addition, 55.3% of participants had at least a very good partial response and 27.6% had a complete or stringent complete response. Moreover, among patients who reached an objective response, the median time to response was 1.2 months. The median progression-free survival and overall survival had not been reached after 10.4 months of follow-up.
According to Dr. Bahlis, the safety profile of elranatamab was manageable. Hematologic events were the most common grade 3 or 4 treatment-emergent adverse events: anemia (36.6%), neutropenia (48.0%), thrombocytopenia (22.0%), lymphopenia (24.4%). Cytokine release syndrome (CRS) occurred in 57.7% of participants, all which were grade 1 or 2 severity. Dr. Bahlis added that the step-up priming regimen that was applied in this study mitigated the rate and severity of CRS. Infections were seen in 66.7% of patients, 35.0% of which were grade 3 or 4.
Copyright ©2022 Medicom Medical Publishers
